Navigation Links
IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial

nd its drug development programs include whether the Company or any of its collaborators will be able to develop pharmaceutical products using the technologies of the Company, whether clinical trial results to date are predictive of results of any future clinical trials, risks associated with completing clinical trials of product candidates, risks involved in the regulatory approval process for the Company's product candidates, the possibility that clinical testing may reveal undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products; whether the cash resources of the Company will be sufficient to fund operations as planned; whether any steps taken by the Company to contain costs will in fact result in sufficient reduction in expenses; reliance on key employees, especially senior management; the risk that the Company may not secure or maintain relationships with collaborators, and the Company's dependence on intellectual property. These factors are more fully discussed in the Company's Annual Report on Form 10-Q filed with the SEC for the quarter ended March 31, 2007 and other periodic reports filed with the SEC. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

CONTACT: Bob De Vaere, Chief Financial Officer of IDM Pharma, Inc.,+1-949-470-6447; or Geoff Curtis of WeissComm Partners, +1-312-550-8138,, for IDM Pharma, Inc. gcurtis@weisscommpartners.com

Web site: http://www.idm-pharma.com/

Ticker Symbol: (NASDAQ-NMS:IDMI)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:3/27/2015)... NEW YORK , March 27, 2015 ... in Santa Ana, California is a ... market for which is estimated at $22 billion in the ... includes the use of FDA-approved Naltrexone in a specially compounded ... (excluding Australia and New ...
(Date:3/27/2015)... Across the global healthcare landscape, the Medical ... development, market education, and regulatory compliance. As emerging markets ... is expected to increase in prominence and follow the ... to research by benchmarking firm, Best Practices, LLC, all ... Medical Affairs. Among companies in India ...
(Date:3/27/2015)... 27, 2015  The quality function within the medical ... meet quality standards at every stage of the product ... leaders also have the challenge of balancing quality and ... who don,t effectively balance these priorities risk funding and ... failure and regulatory scrutiny. For the third ...
Breaking Medicine Technology:Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Medical Affairs Capabilities Expanding in Emerging Marketplaces 2New Medical Device Quality Study Finds Regulatory Environment is Boosting Quality Spending, Especially for Large Companies 2
... (OTC Bulletin Board: HEWA), a leading retail ... separate transactions to acquire all the online assets of ... supplies, and medical equipment, and merge with a newly ... combination will bring together two companies committed to providing ...
... Feb. 15, 2011 Pfenex Inc., an industry ... Technology™ platform and Boehringer Ingelheim International GmbH, a ... contract development and manufacture, announced today that they ... Boehringer Ingelheim with non-exclusive access to the Pfenex ...
Cached Medicine Technology:HealthWarehouse.com Acquires Online Division of Hocks Pharmacy 2Pfenex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the Use of Pfenex Expression Technology™ 2Pfenex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the Use of Pfenex Expression Technology™ 3
(Date:3/28/2015)... (PRWEB) March 28, 2015 An article ... problem which could prove critical to organizations that deal ... a critical aspect of data security, is worsening . ... data security report, every major category out of the ... penetration testing. “With all the craziness that has gone ...
(Date:3/28/2015)... Centurion Service Group will be hosting a live on-site and ... Las Vegas warehouse, located at 4606 Andrews St. Suite 3, ... equipment from hospitals and surgery centers from around the United ... Buyers will find items of all types including anesthesia, endoscopy, ... Erik Tivin, CEO of Centurion. , Among the sale’s ...
(Date:3/28/2015)... 28, 2015 Pitching speed, player’s height, and ... shoulder and elbow injuries, according to new research released today ... ) Specialty Day. , “Our findings indicate that a 10 ... in likelihood of a history of injury, a 10 mile ... increase likelihood of a history of injury, and playing for ...
(Date:3/28/2015)... One in three young athletes who ... today at the American Orthopaedic Society for Sports Medicine’s ... long term success of surgery for patients aged 18 ... from 242 patients who underwent ACL reconstruction between 1993 ... FRACS, from North Sydney Orthopaedic and Sports Medicine Centre. ...
(Date:3/28/2015)... 2015 How best to treat and ... in orthopaedic medicine. While diagnostic hip injections are commonly ... pain etiology, research presented today at the American Orthopaedic ... suggests that pain relief from this diagnostic injection may ... , “Our study looked to assess if the amount ...
Breaking Medicine News(10 mins):Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:Medical Equipment Auction to Take Place in North Las Vegas 2Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2
... patients, according to a recent study, are increasingly turning ... In this context physicians need to be aware of ... patients to the most reliable, accurate and updated information. ... Cancer Center in Philadelphia echoed these ideas at the ...
... Dr. Balakrishna Ganapat Rao Matapurkar, from Maulana Azad Medical ... winning the first patent on organ regeneration from the ... / repairing organs in human beings. ,A few ... patent on this technique. Dr. Matapurkar was able ...
... has come out with a damning disclosure that half the ... Tobacco Day 2001," World Health Organization chief Gro Harlem Brundtland ... because most governments still allowed smoking in public places. She ... no safe permissible levels of second hand smoke. ,"Far ...
... Pfizer on the Indian front has run into rough ... subsidiary Parke-Davis (India). A local court in Hyderabad ... the city. ,The vacation court of the Ranga ... and machinery of Parke-Davis (India) following a petition filed ...
... forward by Brazil, at the annual assembly of the ... breast-feeding for the first six months in all infants. ... on Wednesday after 2 hours of debate where many ... for breast-feeding. ,Nestle, a maker of infant formula ...
... reproductive scientists plan to launch a human cloning clinic, ... 18 months, according to a US infertility specialist, Dr. ... Univeristy of Kentucky, is not medically qualified but holds ... and director of two USD infertility clinics, the Kentucky ...
Cached Medicine News:Health News:Scientists plan human cloning clinic in the United States 2
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,412-7) or contact custom...
... Since 1991 Intersurgical ... breathing filters, heat and ... oxygen therapy products, hand-held ... range of accessories and ...
The Leader in ICU Humidification., ,Available Configurations: , Gas Sampling Port, Straight Flex Tube, Poppel Flex Tube, Luer Port for Pressure, Monitoring/Secretion Removal, Special Use Devices, M...
... line has the right product for any ... from intubated patients to patients with tracheotomies. ... anesthesia and critical care applications., ,The ... for patients and staff members. This entire ...
Medicine Products: